CG Oncology, Inc. (CGON)
Nasdaq: CGON · Biological Products, (No Diagnostic Substances) · Irvine, CA · filing with the SEC since 2023
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Feb 27, 2026 | Mar 28, 2025 | Mar 26, 2024 |
| Revenue | 4,040 | 1,139 | 204 |
| Research and development | 116,641 | 82,102 | 45,752 |
| General and administrative | 73,526 | 33,703 | 9,901 |
| Total operating expenses | · | 115,805 | 55,653 |
| Total costs and expenses | 194,814 | 115,805 | 55,653 |
| Operating income | -190,774 | -114,666 | -55,449 |
| Interest and investment income | 29,931 | 26,624 | 6,904 |
| Other income (expense), net | -152 | 3 | -62 |
| Total non-operating income (expense) | 29,779 | 26,627 | 6,842 |
| Income tax expense | -270 | 1 | 1 |
| Net income including non-controlling interests | -160,995 | -88,039 | -48,607 |
| Net income | -160,995 | -88,039 | -48,607 |
| Preferred dividends | 0 | 0 | 410 |
| Net income to common shareholders | -160,995 | -88,039 | -67,798 |
| Earnings per share, basic | -2.08 | -1.41 | -15.65 |
| Earnings per share, diluted | -2.08 | -1.41 | -15.65 |
| Weighted average shares, basic | 77,303,440 | 62,496,725 | 4,330,933 |
| Weighted average shares, diluted | 77,303,440 | 62,496,725 | 4,330,933 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:OperatingCostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossPreferred dividends paid to preferred holders before common shareholders
us-gaap:PreferredStockDividendsIncomeStatementImpactNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding